About Nuclear respiratory factor 1
Nuclear respiratory factor 1 (NRF1) is a protein
from Homo sapiens identified by UniProt accession
Q16656, 503 residues long.
MolForge cross-references it against 0 known binders and
96 disease associations.
Target properties
| Protein name | Nuclear respiratory factor 1 |
| UniProt accession | Q16656 |
| Gene | NRF1 |
| Organism | Homo sapiens |
| Length | 503 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (96)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.49
- platelet count · score 0.44
- neuroinflammatory disorder · score 0.37
- platelet component distribution width · score 0.35
- Red cell distribution width · score 0.35
- mean platelet volume · score 0.35
- creatinine measurement · score 0.30
- platelet crit · score 0.26
- femoral hernia · score 0.24
- total blood protein measurement · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q16656-F1 | alphafold | PREDICTED | 57.55 | — |
Amino-acid sequence (503 residues)
MEEHGVTQTE HMATIEAHAV AQQVQQVHVA TYTEHSMLSA DEDSPSSPED TSYDDSDILN STAADEVTAH LAAAGPVGMA AAAAVATGKK RKRPHVFESN PSIRKRQQTR LLRKLRATLD EYTTRVGQQA IVLCISPSKP NPVFKVFGAA PLENVVRKYK SMILEDLESA LAEHAPAPQE VNSELPPLTI DGIPVSVDKM TQAQLRAFIP EMLKYSTGRG KPGWGKESCK PIWWPEDIPW ANVRSDVRTE EQKQRVSWTQ ALRTIVKNCY KQHGREDLLY AFEDQQTQTQ ATATHSIAHL VPSQTVVQTF SNPDGTVSLI QVGTGATVAT LADASELPTT VTVAQVNYSA VADGEVEQNW ATLQGGEMTI QTTQASEATQ AVASLAEAAV AASQEMQQGA TVTMALNSEA AAHAVATLAE ATLQGGGQIV LSGETAAAVG ALTGVQDANG LVQIPVSMYQ TVVTSLAQGN GPVQVAMAPV TTRISDSAVT MDGQAVEVVT LEQ
Explore Nuclear respiratory factor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets